Program
Letrozole
Also written as “letrozole”, “Letrozole Tablets 2.5 mg” and “Arm C: Gedatolisib + Palbociclib + Letrozole”.
Its studies are mostly in Breast Neoplasms · Neoplasms · Polycystic Ovary Syndrome · Endometrial Neoplasms · Infertility, led by 7 companies.
Drug pageLetrozole: every studyMany companies study it; this page follows only the 38 they lead. All 340 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 280 open or running | phase 4since Apr 10, 2001 | Apr 10, 2001 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jun 13, 2011 | Jun 13, 2011 | none ahead |
| Egymedicalpediaits history only | 21 open or running | phase 1since Apr 9, 2024 | Apr 9, 2024 | none ahead |
| Hikma Pharmaceuticalsits history only | 20 open or running | phase 1since Jun 3, 2011 | Jun 3, 2011 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Rovi Pharmaceuticals Laboratoriesits history only | 10 open or running | phase 1since Jan 8, 2018 | Jan 8, 2018 | none ahead |
| Sun Pharmaceutical Industriesits history only | 10 open or running | phase 3since Jan 24, 2008 | Jan 24, 2008 | none ahead |
Also a collaborator on its studies: Gilead Sciences, Pfizer and Hoffmann-La Roche.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 21 studies since Apr 10, 2001.
- Jun 1, 2006Phase 2 study in RecurrenceNovartis · NCT00333086 · 36 enrolled · Germany
- Sep 24, 2007Phase 3 study in Breast NeoplasmsNovartis · NCT00535418 · 35 enrolled
- Jan 24, 2008Sun Pharmaceutical Industries’ first study: phase 3 study in InfertilityNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT00610077 · 55 enrolled · India
- Mar 30, 2008Viatris’s first studies: 2 phase 1 studies in HealthyNew to ViatrisViatris · NCT00648154, NCT00648063
- May 29, 2008Phase 4 study in Breast NeoplasmsNovartis · NCT00688909 · 261 enrolled · United States
- Oct 28, 2010Phase 2 study in Breast NeoplasmsNovartis · NCT01231659 · 72 enrolled · Israel
- Jun 3, 2011Hikma Pharmaceuticals’ first studies: 2 phase 1 studies in Breast NeoplasmsNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT01367652, NCT01367626
- Jun 13, 2011Dr. Reddy's Laboratories’ first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01372982, NCT01375452
- Oct 1, 2012Phase 2 study in Breast NeoplasmsNovartis · NCT01698918 · 202 enrolled · United States, Argentina, Brazil and more
- Feb 15, 2017Phase 2 study in Breast NeoplasmsNovartis · NCT03056755 · 383 enrolled · United States, Argentina, Belgium and more
- Jan 8, 2018Rovi Pharmaceuticals Laboratories’ first study: phase 1 study in HealthyNew to Rovi Pharmaceuticals LaboratoriesRovi Pharmaceuticals Laboratories · NCT03401320 · 53 enrolled · Czechia
- Jan 29, 2018Phase 3 study in Breast NeoplasmsNovartis · NCT03439046 · 287 enrolled · Italy
- Apr 9, 2024Egymedicalpedia’s first study: phase 1 study in Polycystic Ovary SyndromeNew to EgymedicalpediaEgymedicalpedia · NCT06367712 · 132 enrolled · Egypt
- Jul 7, 2024No phase study in Polycystic Ovary SyndromeEgymedicalpedia · NCT06507332 · 64 planned · Egypt
TargetBeta
“Cytochrome P450 19A1 inhibitor”ChEMBL 37, by rule
Studies
All 38 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06507332Polycystic Ovary Syndrome · Egypt | – | Recruiting | Egymedicalpedia | Sep 1, 2024 | 64 |
| NCT06367712Polycystic Ovary Syndrome · Egypt | 1 | Completed | Egymedicalpedia | Nov 1, 2023 | 132 |
| NCT03439046Breast Neoplasms · Italy | 3 | Terminated | Novartis | Dec 11, 2023 | 287 |
| NCT03401320Healthy · Czechia | 1 | Completed | Rovi Pharmaceuticals Laboratories | May 17, 2024 | 53 |
| NCT03056755Breast Neoplasms · United States, Argentina, Belgium and more | 2 | Completed | Novartis | Jun 14, 2021 | 383 |
| NCT01698918Breast Neoplasms · United States, Argentina, Brazil and more | 2 | Completed | Novartis | Dec 17, 2015 | 202 |
| NCT01375452Healthy | 1 | Completed | Dr. Reddy's Laboratories | May 2008 | 36 |
| NCT01372982Healthy | 1 | Completed | Dr. Reddy's Laboratories | Jun 2008 | 36 |
| NCT01367652Breast Neoplasms · United States | 1 | Completed | Hikma Pharmaceuticals | Apr 2008 | 28 |
| NCT01367626Breast Neoplasms · United States | 1 | Completed | Hikma Pharmaceuticals | Apr 2008 | 28 |
| NCT01231659Breast Neoplasms · Israel | 2 | Completed | Novartis | Nov 20, 2012 | 72 |
| NCT00688909Breast Neoplasms · United States | 4 | Completed | Novartis | Jun 2009 | 261 |
| NCT00648154Healthy · United States | 1 | Completed | Viatris | Dec 2005 | 24 |
| NCT00648063Healthy · United States | 1 | Completed | Viatris | Dec 2005 | 24 |
| NCT00610077Infertility · India | 3 | Completed | Sun Pharmaceutical Industries | Jul 2006 | 55 |
| NCT00535418Breast Neoplasms | 3 | Completed | Novartis | Jul 2002 | 35 |
| NCT00333086Recurrence · Germany | 2 | Completed | Novartis | Jun 2006 | 36 |
| NCT00333047Breast Neoplasms · Germany | 3 | Completed | Novartis | 24 | |
| NCT00332852Breast Neoplasms · Germany | 3 | Completed | Novartis | Jul 2010 | 655 |
| NCT00332709Osteoporosis · Germany | 3 | Completed | Novartis | Aug 2010 | 83 |
| NCT00330317Breast Neoplasms · United Kingdom | 3 | Completed | Novartis | Mar 2010 | 300 |
| NCT00329940Breast Neoplasms · France | 3 | Completed | Novartis | Jan 2008 | 200 |
| NCT00248170Breast Neoplasms · United States, Australia, Austria and more | 3 | Completed | Novartis | Sep 2014 | 4,172 |
| NCT00247663Breast Neoplasms · Japan | 2 | Completed | Novartis | Dec 2005 | 17 |
| NCT00247650Breast Neoplasms · Canada | 2 | Completed | Novartis | Mar 2007 | 190 |
| NCT00241046Breast Neoplasms | 4 | Terminated | Novartis | Mar 2005 | 13 |
| NCT00240942Endometriosis | 2 | Completed | Novartis | Jun 2006 | 40 |
| NCT00237224Breast Neoplasms · Mexico | 4 | Completed | Novartis | Feb 2007 | 40 |
| NCT00237211Breast Neoplasms · Japan | 2 | Completed | Novartis | Oct 2006 | 31 |
| NCT00237198Breast Neoplasms · Japan | 2 | Completed | Novartis | Jul 2006 | 47 |
| NCT00237133Breast Neoplasms · Brazil | 4 | Completed | Novartis | Jan 2009 | 112 |
| NCT00171847Breast Neoplasms · Germany | 4 | Terminated | Novartis | Oct 2008 | 93 |
| NCT00171808Endometrial Neoplasms · Germany | 2 | Completed | Novartis | May 2010 | 26 |
| NCT00171704Breast Neoplasms · Denmark, United Kingdom | 3 | Completed | Novartis | Mar 2011 | 263 |
| NCT00171340Bone Diseases, Metabolic · Argentina, Australia, Belgium and more | 3 | Completed | Novartis | Feb 2010 | 1,065 |
| NCT00171314Breast Neoplasms · Argentina, Belgium, France and more | 3 | Completed | Novartis | Nov 2010 | 527 |
| NCT00050011Breast Neoplasms · United States, Puerto Rico | 3 | Completed | Novartis | Jan 2009 | 602 |
| NCT00014638Breast Neoplasms · United States | 4 | Completed | Novartis | Mar 2002 |
How it is read
Names in the registry
- “Letrozole”, 40 entries
- “letrozole”, 6 entries
- “Letrozole Tablets 2.5 mg”, 2 entries
- “Arm C: Gedatolisib + Palbociclib + Letrozole”, 1 entry
- “PF-07104091 + PF-07220060 + letrozole dose expansion”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 37 studies
- Neoplasms, 2 studies
- Polycystic Ovary Syndrome, 2 studies
- Endometrial Neoplasms, 2 studies
- Infertility, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.